Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]
In development
Reference number: GID-TA11232
Expected publication date:
The second appraisal committee meeting has been scheduled for 20 November 2025.